Molybdenum cofactor (MoCo) deficiency type B is a very rare, usually severe, autosomal recessive inherited metabolic disorder, caused by biallelic variants in the MOCS2 gene. This defect prevents an essential step in Moco synthesis, necessary for the function of enzymes such as sulfite oxidase, leading to the accumulation of toxic sulfur metabolites and early neurological damage.
Molybdenum cofactor deficiency type B
The MOCS2 gene provides instructions for making molybdopterin synthase, an enzyme that participates in an intermediate step of molybdenum cofactor (MoCo) biosynthesis. This cofactor must bind to several critical enzymes for them to be functional, including sulfite oxidase, xanthine oxidoreductase, and aldehyde oxidase.
When MOCS2 has pathogenic variants, Moco synthesis is not completed correctly. Although the molecular defect occurs at a later stage than that affected in MoCo deficiency type A, the clinical outcome is similar: a simultaneous functional failure of MoCo-dependent enzymes. The most severe consequence is the loss of sulfite oxidase activity, which prevents the conversion of toxic sulfite to sulfate and favors the accumulation of sulfites, S-sulfocysteine, and other neurotoxic metabolites. This can cause neonatal encephalopathy, difficult-to-control seizures, and progressive neurodegeneration. The disease is inherited in an autosomal recessive manner and its exact frequency is unknown; taken together, MoCo deficiencies are considered ultrarare conditions.
Symptoms
The classic form usually begins in the first days or weeks of life. Newborns may appear normal at birth and subsequently develop irritability, feeding difficulties, marked hypotonia, severe encephalopathy, and refractory seizures. Brain lesions can progress rapidly and, at times, simulate a picture of perinatal hypoxia or asphyxia. Without urgent supportive intervention, the prognosis is usually very poor. Atypical or milder forms have been described, generally related to some residual activity.
Disease management
Management of MoCo deficiency type B is mainly supportive and symptomatic, focused on controlling seizures, ensuring nutrition, and treating neurological and respiratory complications. There is no approved specific curative pharmacological treatment for type B. Unlike type A caused by MOCS1, phosphadenine/cPMP therapy does not correct the MOCS2 defect, because the alteration occurs at a later step in the pathway. In some cases, protein or sulfur-containing amino acid restrictions have been used to try to reduce sulfite production, although their clinical benefit is limited.
Genes analyzed
Bibliography
Kumar A, Dejanovic B, Hetsch F, et al. S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency. J Clin Invest. 2017 Dec 1;127(12):4365-4378.
Misko AL, Liang Y, Kohl JB, et al. Delineating the phenotypic spectrum of sulfite oxidase and molybdenum cofactor deficiency. Neurol Genet. 2020 Jul 14;6(4):e486.
Stence NV, Coughlin CR 2nd, Fenton LZ, et al. Distinctive pattern of restricted diffusion in a neonate with molybdenum cofactor deficiency. Pediatr Radiol. 2013 Jul;43(7):882-5.
Macaya A, Brunso L, Fernández-Castillo N, et al. Molybdenum cofactor deficiency presenting as neonatal hyperekplexia: a clinical, biochemical and genetic study. Neuropediatrics. 2005 Dec;36(6):389-94.
